Otsuka Signs On To Promote Two UCB Products Just In Time For Possible Raised Safety Concerns
This article was originally published in PharmAsia News
Executive Summary
Otsuka and UCB have agreed to a co-development and co-promotional deal for the Belgium firm's antiepileptic Keppra (levetiracetam) and anti-TNF alpha drug Cimzia (certolizumab pegol) for the Japanese market while both products currently face potential safety hurdles in the U.S